Polyethylene Glycol Loxenatide Injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Brand
- Fulaimei
- Company
- Jiangsu Hansoh Pharmaceutical
- Medicine type
- Biologic
- Therapeutic area
- Endocrinology & metabolism
- Indications recorded in the public source
- As an adjunct to diet and exercise, alone or in combination with metformin, to improve glycemic control in adults with type 2 diabetes.
- Indication source and scope
- Source date(s): 2025-09-19, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to patients with BMI at least 25 whose glycemic control is inadequate with oral glucose-lowering drugs such as metformin or with insulin. The initial prescription must be issued by a specialist at a secondary-level or higher medical institution.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://mpa.yn.gov.cn/sydw/ynsspypshcyzx/zhxx/201905/t20190510_1231786.html
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.hansoh.cn/upload/file/2025/12/04/6c1bf448605e4989b58de3003357954c.pdf
Open the interactive record, public price references and discussions